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PreviewsT cells (Nishimura et al., 2009), and Reis-
ner and colleagues corroborate this.
Through deconvolution of variance be-
tween groups, the authors identified
TCR-b sequences which were enriched
in AT of mice lacking Perf-DCs. Several
of the identified TCR-b sequences varied
at the nucleotide level while encoding
synonymous codons. Enticingly, this im-
plies Perf-DCs constrain T cell clones,
which recognize specific antigen(s) pre-
sent in AT.
The authors conclude that deletion of
populations of T cells in adipose tissue
helps limit fat mass expansion. This
is a provocative hypothesis and wholly
consistent with their data. However, it rai-
ses several further lines of questions for
which their model does not provide an-
swers. From an immunological perspec-
tive, what are the postulated antigens?
From where are they derived? Are they
adipocyte or even foreign derived?
Answering these questions would un-
doubtedly reveal a fundamental aspect
of the relationship between adipose tis-
sue and the immune system and likely
shed light on why there is such a robust
immune response in adipose tissue.626 Immunity 43, October 20, 2015 ª2015 ElThese findings also do not address the
nature of the signal that causes an in-
crease in fat mass in Perf-DC-deficient
mice. Though incompletely understood,
the regulation of fat mass is under neuro-
endocrine control, with hormones, most
notably leptin being released from adi-
pose tissue, signaling to the feeding and
energy regulatory centers of the central
nervous system. How does deletion or
expansion of T cells alter this homeostatic
loop? It is conceivable that the weight
regulatory effects of Perf-DCs might not
be limited or even found in the adipose
tissue.
Although the immune response to
metabolic perturbations is most robust
in adipose tissue, metabolically induced
and specifically obesity induced changes
in immune populations also occur in other
important tissues, including the liver,
intestine, pancreas, and hypothalamus.
Indeed, perhaps the most parsimonious
explanation for the current observations
is that Perf-DCs limit T cell populations
in the hypothalamus or brainstem in
ways that locally modulate neurons crit-
ical for feeding behavior, satiety and en-
ergy expenditure. Answering these ques-sevier Inc.tions will provide key, fundamental
insights into both metabolism and
immunology.REFERENCES
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Food-specific IgE is central to the pathobiology of food allergy, but not sufficient to induce disease. Chen
et al. (2015) demonstrate that food-elicited reactions require an immature mast cell that generates IL-9 to
induce its own maturation.Acute allergic reactions to foods can
range in severity from mild mouth itching
or abdominal discomfort to severe life-
threatening anaphylaxis. Because there
is no cure or disease-modifying therapy,
the management of food allergic patients
is limited to the use of epinephrine for
accidental ingestions and the strict avoid-ance of diagnosed food allergens. This
prescription is complicated by the finding
of elevated food-specific immunoglobulin
E (IgE), indicative of sensitization, in indi-
viduals with no clinical reaction to
the implicated food. Indeed, although
approximately 8% of U.S. children are
sensitized to peanut, the prevalence ofclinical allergy is approximately 1%–2%
(Liu et al., 2010). The factors that regulate
clinical reactions to food antigens have
been sought for some time but are poorly
understood.
The natural history of repeated oral an-
tigen administration in mice and humans
is the generation of antigen-specific
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Previewstolerance and the acquisition of regulatory
T cells. Murine models of food allergy
circumvent this by administering oral anti-
gens in the presence of strong adjuvants
(cholera toxin, staphylococcal entero-
toxin), by using mutant mice with disrup-
ted regulatory T cell function, or by
sensitizing mice through either disrupted
skin or peritoneal injection with alum. Ge-
netic susceptibility to experimental food
allergy in mice is widely acknowledged
to be strain-specific, despite the signifi-
cant induction of IgE in most strains. A
constant feature among these models is
the involvement of activated mast cells
(MCs) (reviewed in Oyoshi et al., 2014).
MCs are well known effectors of allergic
inflammation. Activated MCs release
secretory granule-associated mediators
such as histamine, generate lipid media-
tors such as cysteinyl leukotrienes
(cysLTs) and platelet activating factor
(PAF), and produce pro-inflammatory cy-
tokines such as tumor necrosis factor
alpha (TNF-a) and interleukin-13 (IL-13).
There are two major subclasses of MCs,
innate and induced. Innate connective tis-
sueMCs (CTMCs), derived independently
of thymic function from fetal liver progen-
itors, reside in stromal tissues, while
induced mucosal MCs (MMCs), derived
from bone marrow (BM) progenitors, are
found in the epithelium of the gut and
lung in the setting of type-2-cell-mediated
inflammation.
The study by Chen et al. (2015) induced
experimental food allergy in BALB/c mice
with ovalbumin (OVA)+alum intraperito-
neal sensitization and repeated oral OVA
challenges. This model has been previ-
ously demonstrated to induce expansion
of MMCs in the small intestine (Brandt
et al., 2003). Moreover, depletion of
MMCs by an antibody directed to c-Kit
or inhibition of MC activation by an anti-
body to IgE or the use of FcεR1 null mice
significantly reduced the development of
diarrhea and gut edema elicited by oral
antigen challenge, indicating the impor-
tance of MC activation for the elicitation
of clinical reactions. Importantly, in the
same OVA+alum model, mice with a tar-
geted deletion of either the IL-9 receptor
(IL9R) or IL-9, a cytokine which promotes
intestinal mastocytosis, were protected
from MMC expansion in the intestine and
MC degranulation and diarrhea induced
by oral antigen, despite intact generation
of OVA-specific IgE and IgG (Osterfeldet al., 2010). Thus IL-9 appears to be a
second signal required for clinical reac-
tivity to oral food antigens.
In the current study, Chen et al. used
this model to identify the cellular source
of IL-9. The investigators first identified
lineage-negative (Lin‒) IL-9-producing
cells in the lamina propria of several sensi-
tized and challenged murine strains. As
expected, they found a correlation be-
tween the number of IL-9+ cells and the
degree of intestinal mastocytosis, MC
activation (as determined by the detection
of mouseMC protease-1, mMCP-1, in the
serum), and antigen-induced diarrhea and
hypothermia across strains. IL-9-produc-
ing cells expressed c-Kit and the receptor
for IL-33 (ST2), contained transcripts for
mMCP-1 and the transcription factor
GATA-2 but not GATA-3, and released
mMCP-1 on ex-vivo IgE cross-linking,
identifying these as MCs and not type 2
innate lymphoid cells (ILC2s). Notably
these cells generated very high amounts
of IL-9 (0.4 pg/ml/cell) and generated
higher amounts (1.2 pg/ml/cell) with IL-
33 stimulation.
MMCs develop exclusively in peripheral
tissues from BM-derived agranular MC
progenitors (MCps) which seed the intes-
tine and lung of naive mice and expand in
the setting of type 2 cell-mediated inflam-
mation.MCps are defined by their expres-
sion of the integrin b7,which is required for
MCp homing to the small intestine (Gurish
et al., 2001) and the inflamed lung (Abonia
et al., 2006), and which is progressively
lostwithmaturationofMCps intohypogra-
nular early MMCs (eMMC) and then fully
granulated MMCs (Bankova et al., 2015).
Chen et al. found that while LincKit+
ST2+b7hi MCps did not produce IL-9, a
hypogranular LincKit+ST2+b7lo cell did.
They went on to identify this cell as an in-
termediate in MC lineage development
by several methods. Using the adoptive
transfer of purified BM MCps (LinLy6C
FcεR1CD41CD71FLK2CD150cKit+
b7hi cells) into irradiated recipients to
reconstitute intestinal MCps, they showed
that antibody directed to a4b7 integrin
preventedMCp reconstitution of the intes-
tinal compartment, as expected, and also
prevented the development of IL-9-pro-
ducing hypogranular MMCs (MMC9s),
mature MMCs, MC degranulation, and
diarrhea in response toOVA+alum sensiti-
zation and oral OVA challenge. Further-
more, isolated intestinal MCps acquiredImmunity 43IL-9 generating capacity when cultured
ex vivo with a combination of IL-4,
TGF-b, and IL-33, and isolated IL-9-pro-
ducing MMC9s cultured with the con-
ventional MC growth factors stem cell
factor (SCF) and IL-3 generated granu-
lated MCs, which lost the capacity to
generate IL-9.
Next, the investigators assessed the re-
quirements for MMC lineage develop-
ment in vivo (Figure 1). Murine strains
that were resistant to experimental food
allergy (IL-4-, IL4R-, STAT6-, or T cell-
deficient) had reduced intestinal MCps,
MMC9s, MMCs, and diarrhea in response
to oral antigen, suggesting regulation at
the level of MCps. By contrast, Ab-medi-
ated depletion of CD4+ cells demon-
strated no effect on intestinal MCps, but
reduced MMC9s, MMCs, and clinical
response to oral antigen, suggesting
CD4+ T cell regulation of theMC transition
from MCps to MMC9s, likely by T helper
2 (Th2) cells. Finally, both IL-9-deficient
and IL9R-deficient strains had normal
numbers of MCps and MMC9s, but
reduced mature MMCs, MC activation,
and response to oral antigen, indicating
that the generation of IL-9 is a critical
checkpoint to generate a fully mature
MMC. As the transfer of WT, but not IL-
9-deficient, MMC9s to irradiated IL-9-
deficient mice restored the induction of
intestinal mastocytosis, MC reactivity,
and response to oral antigen, MMC9s
generated the critical cytokine for their
own maturation. Finally, the authors
demonstrated elevated amounts of tran-
scripts for IL-9 and MC selective prote-
ases such as tryptase, chymase, and
carboxypeptidase in duodenal biopsies
from patients with food allergy, as
compared to control subjects.
The findings by Chen et al. add consid-
erably to our understanding of experi-
mental food allergy and MC biology. First,
they provide substantial evidence for the
role of MMCs, not basophils or CTMCs,
in the IgE-dependent reactions elicited
by oral food challenge. Second, using
careful flow cytometric characterization
of intestinal MMC populations across
time, strains, adoptive transfers, and de-
pletions, they provide clear evidence
that MMC9s are hypogranular MC lineage
intermediates developing in the setting
of type-2-cell-mediated intestinal inflam-
mation. Third, and perhaps most inter-
esting for further study, they find that, October 20, 2015 ª2015 Elsevier Inc. 627
Figure 1. Intestinal Mucosal Mast Cell Lineage Development in Experimental Food Allergy
Mast cell progenitors (MCps) are recruited and expanded in the intestinal mucosa in the setting of T cell-
dependent type-2-cell-mediated inflammation requiring IL-4 + IL4R and STAT6 signaling. MCp devel-
opment into IL-9-producing MMCs (MMC9s) requires CD4+ cells and might be driven by stromal-derived
signals such as IL-33 elicited by the intestinal microbiome. IL-9 production by MMC9s and possibly
alternative sources drives MMC9 maturation into MMCs with characteristic granules, poor proliferative
capacity, and potent reactivity to oral antigen challenge.
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PreviewsMMC9s participate in driving their own
maturation into fully competent MMCs,
but require as yet undetermined strain-
related local tissue signals to activate
this program.
The findings from this study have
several potential implications. First, it is
tempting to speculate that local MMC628 Immunity 43, October 20, 2015 ª2015 Elexpansion might provide a second tis-
sue-level signal required for food allergy,
and the lack of this population may
explain the absence of clinical reactions
in many patients with elevated food-spe-
cific IgE. Second, the granulated MMCs
derived from MMC9s could no longer
generate IL-9, indicating the limits of inter-sevier Inc.preting MC pathobiology based on the
study of granulated cells. Furthermore,
as cytokine producing hypogranular MC
lineage intermediates are also seen in
models of allergic pulmonary inflamma-
tion (Bankova et al., 2015) and helminth
infection (Liu et al., 2013), further studies
of these cells are likely to reveal additional
roles in immunopathology. Third, as
transfer of the gut microbiome from food
allergic mice elicits MC activation and
clinical reactivity to oral antigen in recipi-
ents (Noval Rivas et al., 2013), it seems
likely that the local microbiota could play
a significant role in intestinal MMC devel-
opment and further study of these interac-
tions will help shed light on the programs
that drive MMC9 maturation and license
them for ill.REFERENCES
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